Focused On-demand Library for Protein DBF4 homolog B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q8NFT6

UPID:

DBF4B_HUMAN

Alternative names:

Activator of S phase kinase-like protein 1; Chiffon homolog B; Dbf4-related factor 1

Alternative UPACC:

Q8NFT6; D3DX56; Q8TEX0; Q96B19; Q9H912

Background:

Protein DBF4 homolog B, also known as Activator of S phase kinase-like protein 1, Chiffon homolog B, and Dbf4-related factor 1, plays a pivotal role in DNA replication and cell proliferation. It functions as a regulatory subunit for CDC7, activating its kinase activity. This activation is crucial for the progression of S and M phases of the cell cycle, where the CDC7-DBF4B complex specifically phosphorylates the MCM2 subunit at Ser-40, regulating the initiation of DNA replication.

Therapeutic significance:

Understanding the role of Protein DBF4 homolog B could open doors to potential therapeutic strategies, particularly in diseases where cell proliferation is dysregulated.